{
    "title": "108_hr3299",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medicare Prescription Drug Price \nNegotiation Act''.\n\nSEC. 2. AVAILABILITY OF PRESCRIPTION DRUGS FROM PARTICIPATING \n              MANUFACTURERS AT NEGOTIATED PRICES.\n\n    (a) In General.--Each participating manufacturer of a covered \noutpatient drug shall make available for purchase by any qualified \nFederal health care provider, by each pharmacy, and by each provider of \nservices, physician, practitioner, and supplier under the medicare \nprogram such covered outpatient drug in the amount described in \nsubsection (b) at the price described in subsection (c).\n    (b) Description of Amount of Drugs.--The amount of a covered \noutpatient drug that a participating manufacturer shall make available \nfor purchase under subsection (a) is the sum of--\n            (1) an amount equal to the aggregate amount of the covered \n        outpatient drug dispensed by pharmacies to Medicare \n        beneficiaries; and\n            (2) an amount equal to the aggregate amount of the covered \n        outpatient drug dispensed through qualified Federal health care \n        providers.\n    (c) Description of Price.--\n            (1) In general.--The price at which a participating \n        manufacturer shall make a covered outpatient drug available for \n        purchase under subsection (a) is a price that the Secretary, in \n        conjunction with the Secretary of Defense and the Secretary of \n        Veterans Affairs, negotiate with the manufacturer.\n            (2) Promotion of breakthrough drugs.--\n                    (A) In general.--In conducting negotiations with \n                participating manufacturers under paragraph (1), the \n                Secretary shall take into account the goal of promoting \n                the development of breakthrough drugs.\n                    (B) Definition.--For purposes of this paragraph, a \n                drug is a ``breakthrough drug'' if the Secretary \n                determines it is a new product that will make a \n                significant and major improvement by reducing physical \n                or mental illness, reducing mortality, or reducing \n                disability, and that no other product is available to \n                enrollees that achieves similar results for the same \n                condition.\n    (d) Enforcement.--The United States shall debar a manufacturer of \ndrugs or biologicals that does not comply with the provisions of this \nAct.\n    (e) Dispute Resolution Mechanism.--The Secretary shall establish a \nmechanism (such as an ombudsman) for the resolution of disputes between \nMedicare beneficiaries and prescription drug resellers and drug \nmanufacturers in order to protect such beneficiaries and to ensure \nthat--\n            (1) prescription drug resellers are not artifically \n        increasing prices charged to Medicare beneficiaries (above \n        those negotiated under subsection (c)) in places where there is \n        less competition (such as in rural areas); and\n            (2) such resellers are not colluding on prices in areas \n        with more potential significant competition.\n\nSEC. 3. ADMINISTRATION.\n\n    The Secretary shall issue such regulations as may be necessary to \nimplement this Act.\n\nSEC. 4. REPORTS TO CONGRESS REGARDING EFFECTIVENESS OF ACT.\n\n    (a) In General.--Not later than 2 years after the date of the \nenactment of this Act, and annually thereafter, the Secretary shall \nreport to the Congress regarding the effectiveness of this Act in--\n            (1) protecting Medicare beneficiaries from discriminatory \n        pricing by drug manufacturers, and\n            (2) making prescription drugs available to Medicare \n        beneficiaries at substantially reduced prices.\n    (b) Consultation.--In preparing such reports, the Secretary shall \nconsult with public health experts, affected industries, organizations \nrepresenting consumers and older Americans, and other interested \npersons.\n    (c) Recommendations.--The Secretary shall include in such reports \nany recommendations the Secretary considers appropriate for changes in \nthis Act to further reduce the cost of covered outpatient drugs to \nMedicare beneficiaries.\n\nSEC. 5. DEFINITIONS.\n\n    In this Act:\n            (1) Provider of services.--The term ``provider of \n        services'' has the meaning given that term in section 1861(u) \n        of the Social Security Act (42 U.S.C. 1395x(u)).\n            (2) Physician.--The term ``physician'' has the meaning \n        given that term in section 1861(r) of the Social Security Act \n        (42 U.S.C. 1395x(r)).\n            (3) Practitioner.--The term ``practitioner'' has the \n        meaning given that term in section 1842(b)(18)(C) of the Social \n        Security Act (42 U.S.C. 1395u(b)(18)(C)).\n            (4) Supplier.--The term ``supplier'' has the meaning given \n        that term under section 1842(o) of the Social Security Act (42 \n        U.S.C. 1395u(o)).\n            (5) Covered outpatient drug.--The term ``covered outpatient \n        drug'' has the meaning given that term in section 1927(k)(2) of \n        the Social Security Act (42 U.S.C. 1396r-8(k)(2)).\n            (6) Debar.--The term ``debar'' means to exclude, pursuant \n        to established administrative procedures, from Government \n        contracting and subcontracting for a specified period of time \n        commensurate with the seriousness of the failure or offense or \n        the inadequacy of performance.\n            (7) Medicare beneficiary.--The term ``Medicare \n        beneficiary'' means an individual entitled to benefits under \n        part A of title XVIII of the Social Security Act or enrolled \n        under part B of such title, or both.\n            (8) Participating manufacturer.--The term ``participating \n        manufacturer'' means any manufacturer of drugs or biologicals \n        that, on or after the date of the enactment of this title, \n        enters into a contract or agreement with the United States for \n        the sale or distribution of covered outpatient drugs to the \n        United States.\n            (9) Secretary.--The term ``Secretary'' means the Secretary \n        of Health and Human Services.\n\nSEC. 6. EFFECTIVE DATE.\n\n    The Secretary shall implement this Act as expeditiously as \npracticable and in a manner consistent with the obligations of the \nUnited States."
}